A detailed history of State Street Corp transactions in Humacyte, Inc. stock. As of the latest transaction made, State Street Corp holds 4,764,155 shares of HUMA stock, worth $21.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,764,155
Previous 2,868,626 66.08%
Holding current value
$21.4 Million
Previous $13.8 Million 88.23%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.11 - $9.46 $9.69 Million - $17.9 Million
1,895,529 Added 66.08%
4,764,155 $25.9 Million
Q2 2024

Aug 14, 2024

BUY
$2.87 - $9.1 $4.75 Million - $15.1 Million
1,655,896 Added 136.54%
2,868,626 $13.8 Million
Q1 2024

May 15, 2024

BUY
$2.57 - $4.84 $154,043 - $290,104
59,939 Added 5.2%
1,212,730 $3.77 Million
Q4 2023

Feb 14, 2024

BUY
$1.99 - $3.12 $53,158 - $83,344
26,713 Added 2.37%
1,152,791 $3.27 Million
Q3 2023

Nov 14, 2023

BUY
$2.75 - $4.48 $238,694 - $388,855
86,798 Added 8.35%
1,126,078 $3.3 Million
Q2 2023

Aug 14, 2023

BUY
$2.86 - $4.97 $1.08 Million - $1.88 Million
378,485 Added 57.28%
1,039,280 $2.97 Million
Q1 2023

May 15, 2023

BUY
$2.11 - $3.25 $358,299 - $551,882
169,810 Added 34.59%
660,795 $2.04 Million
Q4 2022

Feb 14, 2023

BUY
$2.02 - $3.62 $146,191 - $261,986
72,372 Added 17.29%
490,985 $1.04 Million
Q3 2022

Nov 15, 2022

BUY
$1.22 - $5.14 $696 - $2,934
571 Added 0.14%
418,613 $1.37 Million
Q2 2022

Aug 15, 2022

BUY
$3.21 - $7.86 $567,653 - $1.39 Million
176,839 Added 73.32%
418,042 $1.34 Million
Q1 2022

May 16, 2022

BUY
$4.65 - $7.4 $797,595 - $1.27 Million
171,526 Added 246.17%
241,203 $1.7 Million
Q4 2021

Feb 14, 2022

BUY
$7.25 - $11.6 $505,158 - $808,253
69,677 New
69,677 $505,000

Others Institutions Holding HUMA

About Humacyte, Inc.


  • Ticker HUMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,007,000
  • Market Cap $463M
  • Description
  • Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...
More about HUMA
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.